A Sensor Network System for Monitoring Short-Term Construction Work Zones

Safety hazards encountered near construction work zones are high, both in number and in the kind. There is a need to monitor traffic in such construction zones in order to improve driver and vehicle safetyIn the past traffic monitoring systems were built with high cost equipment such as inductive plates, video cameras etc. These solutions are too cost{prohibitive and invasive to be used in the large. Wireless sensor networks provide an opportunity space that can be used to address this problem. This thesis specifically targets temporary or short-term construction work zones. We present the design and implementation of a sensor network system targeted at monitoring the flow of traffic through these temporary construction work zones. As opposed to long-term work zones which are common on highways, short-term or temporary work zones remain active for a few hours or a few days at most. As such, instrumenting temporary work zones with monitoring equipment similar to those used in long-term work zones is not practical. Yet, these temporary work zones present an important problem in terms of crashes occurring in and around them. The design for this sensornet-based system for monitoring traffic is (a) inexpensive, (b) rapidly deployable, (c) requires minimal maintenance and (d) non-invasive. In this thesis we present our experiences in building this system, and testing this system in live work zones in the Greater Cleveland are

A Sensor Network System for Monitoring Short-Term Construction Work Zones

Safety hazards encountered near construction work zones are high, both in number and in the kind. There is a need to monitor traffic in such construction zones in order to improve driver and vehicle safetyIn the past traffic monitoring systems were built with high cost equipment such as inductive plates, video cameras etc. These solutions are too cost{prohibitive and invasive to be used in the large. Wireless sensor networks provide an opportunity space that can be used to address this problem. This thesis specifically targets temporary or short-term construction work zones. We present the design and implementation of a sensor network system targeted at monitoring the flow of traffic through these temporary construction work zones. As opposed to long-term work zones which are common on highways, short-term or temporary work zones remain active for a few hours or a few days at most. As such, instrumenting temporary work zones with monitoring equipment similar to those used in long-term work zones is not practical. Yet, these temporary work zones present an important problem in terms of crashes occurring in and around them. The design for this sensornet-based system for monitoring traffic is (a) inexpensive, (b) rapidly deployable, (c) requires minimal maintenance and (d) non-invasive. In this thesis we present our experiences in building this system, and testing this system in live work zones in the Greater Cleveland are

A Sensor Network System for Monitoring Short-Term Construction Work Zones

Safety hazards encountered near construction work zones are high, both in number and in the kind. There is a need to monitor traffic in such construction zones in order to improve driver and vehicle safetyIn the past traffic monitoring systems were built with high cost equipment such as inductive plates, video cameras etc. These solutions are too cost{prohibitive and invasive to be used in the large. Wireless sensor networks provide an opportunity space that can be used to address this problem. This thesis specifically targets temporary or short-term construction work zones. We present the design and implementation of a sensor network system targeted at monitoring the flow of traffic through these temporary construction work zones. As opposed to long-term work zones which are common on highways, short-term or temporary work zones remain active for a few hours or a few days at most. As such, instrumenting temporary work zones with monitoring equipment similar to those used in long-term work zones is not practical. Yet, these temporary work zones present an important problem in terms of crashes occurring in and around them. The design for this sensornet-based system for monitoring traffic is (a) inexpensive, (b) rapidly deployable, (c) requires minimal maintenance and (d) non-invasive. In this thesis we present our experiences in building this system, and testing this system in live work zones in the Greater Cleveland are

Enabling ultra-high dose rate electron beams at a clinical linear accelerator for isocentric treatments

BACKGROUND AND PURPOSE Radiotherapy delivery with ultra-high dose rates (UHDR) has consistently produced normal tissue sparing while maintaining efficacy for tumour control in preclinical studies, known as the FLASH effect. Modified clinical electron linacs have been used for pre-clinical studies at reduced source-surface distance (SSD) and novel intra-operative devices are becoming available. In this context, we modified a clinical linac to deliver 16 MeV UHDR electron beams with an isocentric setup. MATERIALS AND METHODS The first Varian TrueBeam (SN 1001) was clinically operative between 2009-2022, it was then decommissioned and converted into a research platform. The 18 MeV electron beam was converted into the experimental 16 MeV UHDR. Modifications were performed by Varian and included a software patch, thinner scattering foil and beam tuning. The dose rate, beam characteristics and reproducibility were measured with electron applicators at SSD = 100 cm. RESULTS The dose per pulse at isocenter was up to 1.28 Gy/pulse, corresponding to average and instantaneous dose rates up to 256 Gy/s and 3⋅10$^{5}$ Gy/s, respectively. Beam characteristics were equivalent between 16 MeV UHDR and conventional for field sizes up to 10x10cm$^{2}$ and an overall beam reproducibility within ± 2.5% was measured. CONCLUSIONS We report on the first technical conversion of a Varian TrueBeam to produce 16 MeV UHDR electron beams. This research platform will allow isocenter experiments and deliveries with conventional setups up to field sizes of 10x10 cm$^{2}$ within a hospital environment, reducing the gap between preclinical and clinical electron FLASH investigations

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

A Sensor Network System for Monitoring Short-Term Construction Work Zones

Safety hazards encountered near construction work zones are high, both in number and in the kind. There is a need to monitor traffic in such construction zones in order to improve driver and vehicle safetyIn the past traffic monitoring systems were built with high cost equipment such as inductive plates, video cameras etc. These solutions are too cost{prohibitive and invasive to be used in the large. Wireless sensor networks provide an opportunity space that can be used to address this problem. This thesis specifically targets temporary or short-term construction work zones. We present the design and implementation of a sensor network system targeted at monitoring the flow of traffic through these temporary construction work zones. As opposed to long-term work zones which are common on highways, short-term or temporary work zones remain active for a few hours or a few days at most. As such, instrumenting temporary work zones with monitoring equipment similar to those used in long-term work zones is not practical. Yet, these temporary work zones present an important problem in terms of crashes occurring in and around them. The design for this sensornet-based system for monitoring traffic is (a) inexpensive, (b) rapidly deployable, (c) requires minimal maintenance and (d) non-invasive. In this thesis we present our experiences in building this system, and testing this system in live work zones in the Greater Cleveland are

A Mobility Management Framework for Optimizing the Trajectory of a Mobile Base-station

We describe a software framework for prescribing the trajetory path of a mobile sink in a wireless sensor network under an extensible set of optimization criteria. The framework relies on an integrated mobility manager that continuously advises the sink using application-specific network statistics. We focus on a reference mplementation for TinyOS.Through extensive physical experimentation, we show that the mobility manager significantly improves network performance under a range of optimization scenarios